ModernaTX, Inc.
Moderna is dedicated to realizing the promise of mRNA science by creating a new generation of transformative medicines for patients. The company focuses on developing innovative treatments that leverage mRNA technology to fight diseases differently, help more people, and deliver more medicines faster. Moderna's platform enables rapid design, research, and testing of multiple mRNA medicines, aiming to make life-saving treatments accessible to a broad population.
Industries
Nr. of Employees
Very Large (1000+)
ModernaTX, Inc.
Patents
User defined functions for database query languages based on call-back functions
US-11216454-B1
View DetailsCompositions comprising synthetic polynucleotides encoding CRISPR related proteins and synthetic sgRNAs and methods of use
US-11027025-B2
View DetailsAlternative nucleic acid molecules containing reduced uracil content and uses thereof
US-10072057-B2
View Details
User defined functions for database query languages based on call-back functions
US-11216454-B1
View DetailsCompositions comprising synthetic polynucleotides encoding CRISPR related proteins and synthetic sgRNAs and methods of use
US-11027025-B2
View DetailsAlternative nucleic acid molecules containing reduced uracil content and uses thereof
US-10072057-B2
View DetailsProducts
mRESVIA (Respiratory Syncytial Virus vaccine, mRNA)
mRNA-based vaccine candidate for prevention of respiratory syncytial virus (RSV).
mNEXSPIKE (COVID-19 vaccine, mRNA)
mRNA COVID-19 vaccine candidate/formulation referenced for regulatory approval.
SPIKEVAX (COVID-19 vaccine, mRNA)
mRNA COVID-19 vaccine formulation listed in product catalog.
Moderna COVID-19 Vaccine (2024-2025 Formula)
Seasonal/updated formulation of an mRNA COVID-19 vaccine referenced for 2024–2025 usage.
mRESVIA (Respiratory Syncytial Virus vaccine, mRNA)
mRNA-based vaccine candidate for prevention of respiratory syncytial virus (RSV).
mNEXSPIKE (COVID-19 vaccine, mRNA)
mRNA COVID-19 vaccine candidate/formulation referenced for regulatory approval.
SPIKEVAX (COVID-19 vaccine, mRNA)
mRNA COVID-19 vaccine formulation listed in product catalog.
Moderna COVID-19 Vaccine (2024-2025 Formula)
Seasonal/updated formulation of an mRNA COVID-19 vaccine referenced for 2024–2025 usage.
Services
Online portal for reporting adverse events and intake workflows for safety monitoring.
Regional analytical laboratory intended to support product testing, method development and regulatory interactions in Europe.
Resources and processes for supplier onboarding, purchase order management and invoicing.
Online portal for reporting adverse events and intake workflows for safety monitoring.
Regional analytical laboratory intended to support product testing, method development and regulatory interactions in Europe.
Resources and processes for supplier onboarding, purchase order management and invoicing.
Expertise Areas
- mRNA therapeutics research and development
- Vaccine development and clinical programs
- Clinical trial management
- Manufacturing scale-up and process development
Key Technologies
- mRNA therapeutic platform
- Delivery technologies for nucleic acids
- Vaccine development platforms
- Cloud-based analytics
News & Updates
Announcement of positive results from phase 3 trials for a seasonal influenza vaccine.
Moderna's RSV vaccine, mRESVIA, received FDA approval for use in certain adult populations.
Upcoming presentation at Barclays' series on scientific developments.
Announcement of Moderna's new COVID-19 vaccine, mNEXSPIKE.
FDA approval for Moderna's COVID-19 vaccine, mNEXSPIKE.
Announcement of positive results from phase 3 trials for a seasonal influenza vaccine.
Moderna's RSV vaccine, mRESVIA, received FDA approval for use in certain adult populations.
Upcoming presentation at Barclays' series on scientific developments.
Announcement of Moderna's new COVID-19 vaccine, mNEXSPIKE.
FDA approval for Moderna's COVID-19 vaccine, mNEXSPIKE.